“…In our institution, the presence of more than three progressive LCH bone lesions is generally considered as a requirement for chemotherapy. The reported sensitivity of RBS varies between 35 % and 94 % [11,13,[15][16][17][18][19][20][21][22], reaching 100 % in cases of a single bone lesion in two studies [20,22]. Furthermore, local treatment of areas susceptible to fracture may be required [9,12,13], and these areas must be identified.…”